OCT 07, 2021 7:30 AM PDT

Uncover All Hallmarks of Cancer with Multiplex Gene and Protein Assays Using Luminex Technology

Sponsored by: LUMINEX
C.E. Credits: P.A.C.E. CE Florida CE
Speaker

Abstract

Advances in cancer research have improved our understanding of the complex interactions between tumors, their microenvironment and the host immune response. The evolving research field of immuno-oncology focuses on an individual’s immune system as innovative treatment approaches to combat cancer. The goal of cancer immunotherapies is to initiate a self-sustaining cycle of cancer immunity, overcome tumor evasion mechanisms and promote conditions that favor immune protection. Immune checkpoint molecules have been identified as critical players in the regulation of NK cell- and T cell-mediated immune responses. Besides intact transmembrane proteins, soluble isoforms and variants of checkpoint molecules function as immune adjuvants or decoy receptors and may also influence efficacy of checkpoint modulator drugs. The systematic analysis of these soluble biomarkers and other key targets should help to shed light on all crucial features of cancer including the regulation of checkpoint pathways, tumor growth and metastasis to facilitate research for future immunotherapeutic treatments. Moreover, analyzing the protein cargo of cancer cell-derived exosomes and the levels of a broader set of immunomodulatory markers will allow researchers to further decipher the complex interplay of mediators implicated in cancer development and progression. 

This presentation will provide an understanding of Luminex xMAP-based multiplex immunoassay solutions (RUO) that enable the simultaneous detection of multiple soluble immune stimulatory and inhibitory factors, providing a more complete picture of cancer immunity in a blood sample, both on the transcript and protein level. 

 

Learning Objectives:

1. Outline immunoassay solutions to advance cancer research.

2. Discuss cancer-derived exosomes as novel class of biomarkers.

3. Break down immuno-monitoring approaches to characterize and understand key changes in the immune response to cancer.

4. Explain mRNA cancer biomarkers using Invitrogen™ QuantiGene™ Plex assays for multiplex, high-throughput gene expression analysis.

5. Explain protein cancer biomarkers using Invitrogen™ ProcartaPlex™ assays for multiplex protein analysis.
 


Show Resources
You May Also Like
SEP 14, 2021 7:00 AM PDT
C.E. CREDITS
SEP 14, 2021 7:00 AM PDT
Date: September 14, 2021 Time: 7am PDT, 10am EDT, 4pm CEST A conventional thermal cycler has long been a commodity product in the lab and end-point PCR techniques can be completed almost wit...
SEP 17, 2021 12:00 PM CST
C.E. CREDITS
SEP 17, 2021 12:00 PM CST
Date: September 16, 2021 Time: 9:00pm (PDT), 12:00am (EDT) 3D cellular models like organoids and spheroids offer an opportunity to better understand complex biology in a physiologically rele...
NOV 09, 2021 11:00 AM PST
C.E. CREDITS
NOV 09, 2021 11:00 AM PST
Date: November 09, 2021 Time: 11:00am (PDT), 02:00pm (EDT) Clinical translation of human pluripotent stem cells (hPSCs) requires advanced strategies that ensure safe and robust long-term gro...
DEC 01, 2021 7:00 AM PST
C.E. CREDITS
DEC 01, 2021 7:00 AM PST
Date: December 01, 2021 Time: 7:00am (PST), 10:00am (EST) In the era of immuno-oncology, there is a growing need for the identification of new biomarkers predictive for sensitivity to anti-P...
OCT 27, 2021 6:00 AM PDT
C.E. CREDITS
OCT 27, 2021 6:00 AM PDT
Date: October 27, 2021 Time: 6:00 AM PDT, 9:00 AM EDT Etanercept is a recombinant Fc fusion protein therapeutic that has a complex distribution of post-translation modifications (PTM), such...
AUG 24, 2021 11:00 AM PDT
C.E. CREDITS
AUG 24, 2021 11:00 AM PDT
Date: August 24, 2021 Time: 11:00am (PDT), 1:00pm (EDT) Electron-based dissociation mechanisms have shown great promise for advanced characterization of biomolecules. However, routine adopti...
Loading Comments...
Show Resources